We are regularly asked to characterize the market backdrop for potential life sciences IPOs. While biotech ETF performance can offer a glimpse at current conditions, we dug deeper and analyzed recent biopharma index strength, IPO activity and follow-on offerings, among other metrics.
Our analysis indicates the market remains strong, albeit with some signs of moderation.
An initial public offering marks an important milestone in a company’s journey — a positive one, assuming the process is meticulously designed and implemented. Errors in planning and communication, however, can turn a vital Wall Street debut into a credibility-damaging flop.
Unfortunately, there’s no shortage of examples of IPOs gone wrong. One case of fairly recent vintage: meal-kit delivery service Blue Apron.
Completing a successful IPO is a major milestone in the life of a company. Deciding to embark on the journey to public markets is an exciting time, but it’s essential to ensure that your company is ready. Once the process kicks off, there’s no time to go back and complete important tasks — like meeting with institutional investors and finalizing your company message — that should have been done prior to your organizational meeting. This is when you’ll discuss your offering process with management, counsel, and other advisors.
A false start can significantly damage your company’s credibility on the Street. So how do you know if your company is ready? We’ve compiled a list of six key questions to consider that will help you evaluate whether your company is ready for an IPO.
Making the jump from private to public markets can be an exciting endeavor, but you have to make sure your company is in the right position or you risk damaging your credibility on the Street. So how will you know when you’re ready? We’ve compiled a list of seven red flags to look out for that mean you’re not quite there. Remember, an IPO takes time and it pays to do your due diligence.
As head of business development for Westwicke, I always look forward to a jam-packed, action-filled week of conversations. This year did not disappoint.
With almost 50 meetings scheduled, I had the pleasure of meeting with many compelling private and public healthcare companies. And there was no shortage of innovation, grit, and creativity this year. I found many management teams determined to advance their science, technology, and businesses in 2018.
It’s time to start planning for the biggest healthcare investment conference of the year. For four days, investors, bankers, analysts, and business executives will be at the J.P. Morgan Healthcare Conference, from Monday January 8, 2018 through Thursday January 11, 2018, amid back-to-back sessions, corporate pitches, and networking events. From getting organized to figuring out how to maximize meeting time, it’s important to lock down your company’s approach so you can navigate the chaos with ease. Here is a checklist to help you prepare for the J.P. Morgan conference so that you make sure your time spent is a success.
Whether it’s your first J.P. Morgan Healthcare Conference or your 36th, if you are involved in the healthcare sector in any way, you know J.P. Morgan is the super bowl of healthcare conferences and for four days, it becomes the epicenter of healthcare. The attendance is staggering with approximately 20,000 healthcare professionals ranging from institutional investors, private equity and venture capital investors, bankers, analysts, and company executives all gathering to see the next new thing in healthcare. It is the place to be for healthcare executives to start the year.
Posted on September 14th, 2017. Posted by Patti Bank
Attending Wall Street investment banking conferences is a large part of a strategic investor relations plan. Along with non-deal road shows, management’s visibility and interaction with buy-side accounts during one-on-one meetings are critical for conveying your story to potential investors, addressing unanswered questions, and expanding on an investment theme. But, finding the appropriate conference strategy can be harder than it seems, especially when it comes to lining up a successful meeting schedule with key buy-side accounts.
At Westwicke, we’re often asked for our opinion on the state of the market for new public offerings. And the sad truth is that for all but a fortunate few, the IPO window has been shut tight for more than a year.
But the IPO market, like all markets, is cyclical. This bearish view of new public offerings will eventually turn, just as it has many times before.
At some point during your company’s growth, you will need to share sensitive data with investors and financial professionals by using a data room. In the old days, a data room was just that: a room filled with printed files and reams of paper containing patent descriptions, clinical data, and financial projections.
Today, data rooms are usually virtual. And with hackers increasing their efforts (and their ability) to steal sensitive data, it’s vital you consider security as well as service and convenience as you evaluate data room solutions.